Fiche société
HK inno.N Corporation
Traitements, essais et publications liés.
Traitements4programmes
Essais1liés
Publications6liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Amlodipine 10 mg + Valsartan 160 mgTo evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia | Hypertension | Phase 3 | À vérifier | À vérifier | |
| Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mgTo evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia | Hypertension | Phase 3 | À vérifier | À vérifier | |
| Valsartan 160 mg + Rosuvastatin 20 mgTo evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia | Hypertension | Phase 3 | À vérifier | À vérifier | |
| Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mgTo evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia | Hypertension | Phase 3 | À vérifier | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg | Hypertension | Phase 3 | NCT03536598 | Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia | COMPLETED |
Publications
6| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Valsartan 160 mg + Rosuvastatin 20 mg | A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. | Drug design, development and therapy | ||
| Amlodipine 10 mg + Valsartan 160 mg | Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure. | High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension | ||
| Valsartan 160 mg + Rosuvastatin 20 mg | Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. | Korean circulation journal | ||
| Amlodipine 10 mg + Valsartan 160 mg | Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy. | The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology | ||
| Amlodipine 10 mg + Valsartan 160 mg | Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure. | Current hypertension reviews | ||
| Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg | Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. | Advances in therapy |